Patents by Inventor Jason Bryant CROSS

Jason Bryant CROSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230312588
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: October 5, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230295173
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: September 21, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230008047
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 12, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 11434233
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 6, 2022
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Imidazopiperazine inhibitors of transcription activating proteins
    Patent number: 11058688
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 13, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Philip Jones, Jason Bryant Cross, Christopher L. Carroll, Timothy Joseph McAfoos, Pijus Kumar Mandal
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11046649
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Timothy McAfoos, Jason Bryant Cross, Michael J. Soth
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20210047311
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 18, 2021
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Suyambu Kesava Vijayan RAMASWAMY, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • Imidazopiperazinone inhibitors of transcription activating proteins
    Patent number: 10899769
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Gang Liu, Philip Jones, Jason Bryant Cross, Timothy Joseph Mcafoos, Christopher L. Carroll, Richard T. Lewis
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10800769
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: October 13, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10800774
    Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 13, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Zhijun Kang, Michael Garrett Johnson, Sarah Lively
  • Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
    Patent number: 10745420
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Michael Garrett Johnson, Sarah Lively
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20200102296
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: July 10, 2019
    Publication date: April 2, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Suyambu Kesava Vijayan RAMASWAMY, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE
    Publication number: 20200024236
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 23, 2020
    Inventors: Richard T. LEWIS, Matthew HAMILTON, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Timothy MCAFOOS, Jason Bryant CROSS, Michael J. SOTH
  • TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE
    Publication number: 20190367536
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Michael Garrett JOHNSON, Sarah LIVELY
  • IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190308978
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: April 8, 2019
    Publication date: October 10, 2019
    Inventors: Kang LE, Michael J. SOTH, Gang LIU, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS, Christopher L. CARROLL, Richard T. LEWIS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190298729
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
    Patent number: 10421765
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 24, 2019
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Michael Garrett Johnson, Sarah Lively
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10392376
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 27, 2019
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190055240
    Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Zhijun KANG, Michael Garrett JOHNSON, Sarah LIVELY
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190016713
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Suyambu Kesava Vijayan RAMASWAMY, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE